Pianificazione, gestione ed esecuzione delle attività di Controllo Qualità relative ai prodotti IVD della linea di Diagnostica Molecolare in conformità ai requisiti della UNI EN ISO 9001:2015 e UNI CEI EN ISO 13485:2016. Stesura della documentazione di controllo qualità in collaborazione con i reparti di Quality Assurance e Regulatory Affairs. Verifica ed approvazione della documentazione di rilascio prodotti relativa a tutte le fasi di produzione, dal controllo in ingresso delle materie prime… Show more Pianificazione, gestione ed esecuzione delle attività di Controllo Qualità relative ai prodotti IVD della linea di Diagnostica Molecolare in conformità ai requisiti della UNI EN ISO 9001:2015 e UNI CEI EN ISO 13485:2016. Stesura della documentazione di controllo qualità in collaborazione con i reparti di Quality Assurance e Regulatory Affairs. Verifica ed approvazione della documentazione di rilascio prodotti relativa a tutte le fasi di produzione, dal controllo in ingresso delle materie prime ai controlli su bulks, semilavorati e prodotti finiti. Gestione di non-conformità, deviazioni e reclami. Esecuzione e verifica delle attività di manutenzione periodica su tutta la strumentazione di laboratorio. Show less

Nucleic Acid Testing UnitSentinel CH. SpAhttp://www.sentineldiagnostics.com

I took part in the research activities in order to identify new antibodies against Diffuse Large B-Cell lymphoma (DLBCL) using the technique of "Phage Display". Specific antibodies are selected through interaction of phage libraries (expressing synthetic antibodies (scFv) on the phage surface) with DLBCL cell lines in vitro and subsequent assessment of their selective cytotoxic activity on cancer cells.Techniques used: expansion and production of phage libraries; biopanning on cell… Show more I took part in the research activities in order to identify new antibodies against Diffuse Large B-Cell lymphoma (DLBCL) using the technique of "Phage Display". Specific antibodies are selected through interaction of phage libraries (expressing synthetic antibodies (scFv) on the phage surface) with DLBCL cell lines in vitro and subsequent assessment of their selective cytotoxic activity on cancer cells.Techniques used: expansion and production of phage libraries; biopanning on cell lines; production of antibodies in E. coli (TG1, BL21 strains); cloning in phagemids and plasmids; cell culture; transfections and production of antibodies in mammalian cells; SDS-Page; Western Blot. Show less

I worked on two research projects:the first was based on the application of PAT-ChIP, a technique of chromatin immuno-precipitation coupled to sequencing of genomic DNA from paraffin-embedded tissues, with the aim to identify possible alterations in epigenetic profile of patient as possible cause of resistance to chemotherapy.The second was focused on the technique of "cell tracking" through infection of cell lines with a lentiviral vector library containing sequences of… Show more I worked on two research projects:the first was based on the application of PAT-ChIP, a technique of chromatin immuno-precipitation coupled to sequencing of genomic DNA from paraffin-embedded tissues, with the aim to identify possible alterations in epigenetic profile of patient as possible cause of resistance to chemotherapy.The second was focused on the technique of "cell tracking" through infection of cell lines with a lentiviral vector library containing sequences of oligonucleotides to be used as "barcodes" to monitor different clones in subsequent in vivo experiments.Techniques used: microtome cut of paraffin tissue sections; Chromatin IP from paraffin-embedded tissue ; library prep. for Illumina sequencing; PCR; qPCR; extraction of genomic DNA / RNA from normal and paraffin embedded tissues; cell culture; transfection and infection of cell lines with lentiviral vectors. Show less

Responsible for technical and operational characterization of novel inhibitors of mitochondrial Permeability Transition Pore (mPTP), a molecular target involved in several types of diseases and particularly in ischemia / reperfusion injury in myocardial infarction. My activities were focused on the execution and implementation of the major biochemical assays used to measure the activity of the compounds on mitochondria isolated from murine organs, using an automated liquid handling platform… Show more Responsible for technical and operational characterization of novel inhibitors of mitochondrial Permeability Transition Pore (mPTP), a molecular target involved in several types of diseases and particularly in ischemia / reperfusion injury in myocardial infarction. My activities were focused on the execution and implementation of the major biochemical assays used to measure the activity of the compounds on mitochondria isolated from murine organs, using an automated liquid handling platform (Tecan, Freedom EVO series). I also worked work in vivo with mice using the "Langendorff" model for measuring ex vivo levels of LDH released from heart after ischemia.Techniques used: excision of murine organs; protocols for isolation of mitochondria from different murine and human tissues ; measurement of mitochondrial respiration with oxygraph; biochemical assays (absorbance and fluorescence) on isolated mitochondria (swelling and mitochondrial calcium uptake); set-up of the same assays in 96wells format with robotic system; SDS-Page; Western Blot. Show less

I took part, in collaboration with EIO Experimental Oncology, in a phase I-II clinical study with the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients affected by different types of tumor (mainly advanced melanoma). I was responsible of measuring experimentally the correlation between biological and therapeutic effect of the drug, using an innovative method to detect histone acetylation levels by flow cytometry. I then worked on several research projects… Show more I took part, in collaboration with EIO Experimental Oncology, in a phase I-II clinical study with the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients affected by different types of tumor (mainly advanced melanoma). I was responsible of measuring experimentally the correlation between biological and therapeutic effect of the drug, using an innovative method to detect histone acetylation levels by flow cytometry. I then worked on several research projects focused on studying deregulation of chromatin modifiers in tumorigenesis. In particular, I investigated the role of Histone Deacetylases in tumor cell lines as potential target for new oncologic therapies, focusing on the screening of potential inhibitors (HDACi). Over the last two years I have been responsible for the development of an innovative technique based on the use of restriction enzymes in order to obtain a systematic mapping of nuclease accessible sites in the human genome.Techniques used: isolation of human peripheral blood lymphocytes; FACS staining of lymphocytes and cell lines (technique published); cell culture; drug treatment of cell lines; PCR; qPCR; cloning in plasmids; DNA and RNA preps from cells and tissues and analysis on agarose gel; SDS-Page; Western Blot; isolation and analysis of genomic DNA; DNaseI hypersensitive sites assays; Southern blot; clone screening and analysis of DNA sequences. Show less